2/14/2013 6:18:51 AM
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced its unaudited consolidated financial results for the quarter ended December 31, 2012 under International Financial Reporting Standards (IFRS).
Key Highlights (Q3 FY13)
•Consolidated revenues for Q3 FY13 at Rs. 28.7 billion, recorded YoY growth of 23%#. Consolidated revenues for 9 months FY13 at Rs. 82.9 billion, recorded YoY growth of 26%#.? Revenues from the Global Generics segment for Q3 FY13 at Rs. 20.8 billion, recorded a YoY growth of 24%# primarily driven by North America and the Emerging market territories.
comments powered by